AstraZeneca wins reprieve from Pulmicort generics; Merck's second Fosamax trial set to go;

@FiercePharma: Analysts expect nanotech drug delivery boom despite safety concerns. Article | Follow @FiercePharma

@EricPFierce: Pfizer recalls 52,000 bottles of its thyroid pill Levoxyl because of a bad odor. More | Follow @EricPFierce

> AstraZeneca ($AZN) has time to fight for its Pulmicort Respules patent, thanks to a court ruling that blocks generic copies till April 12. Report

> Merck's ($MRK) second Fosamax trial over claims involving femur fractures is set to begin next week after the first ended in a mistrial because the plaintiff developed a serious health complication. Report

> Navidea Biopharmaceuticals ($NAVB) said its diagnostic agent Lymphoseek effectively identified sentinel lymph nodes in patients with head and neck cancer, paving the way for expanded use of the drug. Report | More

> Mylan ($MYL) won the FDA's approval for its generic version of Valeant's herpes ointment Zovirax. Report

> Roche ($RHHBY) launched its new test for diagnosis and monitoring of thyroid cancer, Elacsys Calcitonin. Report | More

> Slovenia's Krka hiked its dividend by 7% to €1.61 ($2.07) per share. Report

> Australian officials said increasing the patent life on drugs has already cost the country $200 million a year in drug spending. Report

Medical Device News

@FierceMedDev: Dako gains FDA blessing for breast cancer antibody Dx agent. More | Follow @FierceMedDev

@MarkHFierce: Japan is dropping reimbursement rates for interventional cardiology devices. Not a good development for business. Story | Follow @MarkHFierce

 @DamianFierce: Bausch + Lomb has a date with the FDA for its intraocular lens implant. Article | Follow @DamianFierce

> New Dx chip allows for liquid diagnosis of prostate cancer advance. More

> Roche rolls out thyroid cancer Dx. Story

> Navidea touts PhIII data on Lymphoseek for head and neck cancer. Article

Biotech News

@FierceBiotech: #1 biotech billionaire on our list? @BillGates | Full report | Follow @FierceBiotech

@JohnCFierce: The biotech gods taketh away, and they giveth. Regeneron expanding, adding 400 jobs. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> Merrimack's lead lung cancer drug flunks first of three PhII tests. Article

> Can Merck use animal data to make its case against Lunesta, Ambien? More

> Bristol-Myers shuttering Amylin's San Diego HQ, laying off hundreds. Report

> Celgene-backed Agios and Foundation partner in breakthrough cancer strategy. News

Pharma Manufacturing News

> Industry ready to resurrect track and trace negotiations. Report

> Pfizer has another recall tied to smelly drugs. More

> Canada compounding pharmacy linked to weak chemo drugs. Story

> Frazier grabs AndersonBrecon as it bulks up in packaging. Article

Vaccines News

> JAMA paper delves into Merck staph vaccine flunk. Item

> Text message campaign fails to boost vaccination rate. Article

> U.S. keeping rubella at bay as virus takes toll globally. More

> Autism argument again undermined by vaccine data. Story

> Merck vax condemning pox to past. Report

And Finally... A monetary reason why Alzheimer's treatments are sorely needed: The cost of caring for dementia patients has risen to $109 billion annually, topping heart disease and cancer. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.